Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

IntraVenous Immune Boost

Objective

What if we could finally treat metastatic patients and uncurable cancers like sarcomas ?
HEPHAISTOS-Pharma developed ONCO-Boost, the first-in-class intravenous TLR4 immunostimulant that will be a game changer in immunotherapy. This innovation was discovered after 40 years of research from a woman entrepreneur who developed a mature, scalable, disruptive and eco-friendly platform. ONCO-Boost can cure hard to treat cancers as a stand-alone treatment but can also increase the efficacy of existing treatments. Our cure is injected intravenously and this changes everything, we can offer therapeutic options for patients with metastatic cancers and hardly accessible tumors. As such, ONCO-Boost can cure 10x more patients than competitors, all limited to intratumoral injection. HEPHAISTOS' ambition is to become the European leader in immunostimulants, with a platform able to supply the market with large quantities of drugs, able to save millions of patients each year.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

HEPHAISTOS-PHARMA
Net EU contribution
€ 2 249 749,00
Address
21 RUE JEAN ROSTAND
91400 Orsay
France
SME
Yes
Region
Ile-de-France Ile-de-France Essonne
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 6 910 955,50

Participants (1)